Similar treatment outcomes with Ginkgo biloba extract EGb 761 and donepezil in Alzheimer's dementia in very old age: A retrospective observational study

International Journal of Clinical Pharmacology and Therapeutics

Volumn 56, Issue 3, 2018, Pages 130-133

  Rapp, Michael ^a   Burkart, Martin ^b   Kohlmann, Thomas ^c   Bohlken, Jens ^a  

^a Praxis Bohlken Otto Schultes Platzek   (Germany)

^b DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Alzheimer's disease; Dementia; Donepezil; EGb 761; Ginkgo biloba extract; Oldest old; Safety; Treatment outcome

Indexed keywords

DONEPEZIL; GINKGO BILOBA EXTRACT; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE; PLANT EXTRACT;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OBSERVATIONAL STUDY; PILOT STUDY; RETROSPECTIVE STUDY; SYMPTOM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; COMPARATIVE STUDY; DEMENTIA ASSESSMENT; DRUG EFFECTS; PATHOPHYSIOLOGY;

AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION; FEMALE; HUMANS; INDANS; MALE; MENTAL STATUS AND DEMENTIA TESTS; NOOTROPIC AGENTS; PIPERIDINES; PLANT EXTRACTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85042373812     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP203103     Document Type: Article

References (16)

1. Lucca U, Tettamanti M, Logroscino G, Tiraboschi P, Landi C, Sacco L, Garrì M, Ammesso S, Bertinotti C, Biotti A, Gargantini E, Piedicorcia A, Nobili A, Pasina L, Franchi C, Djade CD, Riva E, Recchia A. Prevalence of dementia in the oldest old: the Monzino 80-plus population based study. Alzheimers Dement. 2015; 11: 258-70.e3. Cross-Ref PubMed
2. Lautenschlager NT, Ihl R, Müller WE. Ginkgo biloba extract EGb 761® in the context of current developments in the diagnosis and treatment of age-related cognitive decline and Alzheimer's disease: a research perspective. Int Psychogeriatr. 2012; 24 (Suppl 1): S46-S50. CrossRef PubMed
3. Tan MS, Yu JT, Tan CC, Wang HF, Meng XF, Wang C, Jiang T, Zhu XC, Tan L. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2015; 43: 589-603. PubMed
4. Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010; 10: 14. CrossRef PubMed
5. Gauthier S, Schlaefke S. Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging. 2014; 9: 2065-2077. CrossRef PubMed
6. Kasper S. Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials. Wien Med Wochenschr. 2015; 165: 217-228. CrossRef PubMed
7. Schulz M, Bohlken J, Schulz M, Hering R, von Stillfried D, Bätzing-Feigenbaum J. [Pharmacological treatment of patients with dementia in German claims data - specific consideration of regional variation] Report in German. Central Research Institute of Ambulatory Health Care in Germany (Zi), Versorgungsatlas-Report No.15/07. Berlin, 2015. http://www.versorgungsatlas.de/themen/alle-analysen-nach-datum-sortiert/?tab=6&uid=54.
8. Leinonen A, Koponen M, Hartikainen S. Systematic Review: representativeness of participants in RCTs of acetylcholinesterase inhibitors. PLoS One. 2015; 10: e0124500 CrossRef PubMed
9. World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. 1993.
10. Folstein MF, Folstein SE, McHugh PR. "Minimental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-198. CrossRef PubMed
11. Kalbe E, Kessler J, Calabrese P, Smith R, Passmore AP, Brand M, Bullock R. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry. 2004; 19: 136-143. CrossRef PubMed
12. Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, Heyman A. The consortium to establish a registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology. 1994; 44: 609-614. CrossRef PubMed
13. Graf C. The Lawton instrumental activities of daily living (IADL) scale. Medsurg Nurs. 2009; 18: 315-316. PubMed
14. Harper L, Barkhof F, Scheltens P, Schott JM, Fox NC. An algorithmic approach to structural imaging in dementia. J Neurol Neurosurg Psychiatry. 2014; 85: 692-698. CrossRef PubMed
15. Czeche S, Schüssel K, Franzmann A, Burkart M, Schulz M. Dosage strength is associated with medication persistence with Ginkgo biloba drug products: a cohort study of ambulatory drug claims data in Germany. BMC Complement Altern Med. 2013; 13: 278: CrossRef PubMed
16. Bohlken J, Weber S, Rapp MA, Kostev K. Continuous treatment with antidementia drugs in Germany 2003-2013: a retrospective database analysis. Int Psychogeriatr. 2015; 27: 1335-1342. CrossRef PubMed